Gilead Sciences, Inc.
Bear Case (25th pct.)
-27.4% vs price
Base Case (Median)
17.7% vs price
Bull Case (75th pct.)
25.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $153.57 | 17.7% | High (40%) |
| PE Comparable | $163.41 | 25.2% | Medium (25%) |
| Growth Trajectory DCF | $247.29 | 89.5% | Medium (20%) |
| Graham Number | $54.90 | -57.9% | Medium (40%) |
| EV/EBITDA | $109.16 | -16.4% | Medium (20%) |
| EV/FCF | $164.45 | 26.0% | Medium (20%) |
| Earnings Power Value | $80.39 | -38.4% | Medium (50%) |
Based on 7 out of 8 methods, GILD appears fairly valued at the current price of $130.52. The base case fair value of $153.57 implies 17.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.